Search Results - "Shaefer, Mark"

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States by Ross, Lisa L, Shortino, Denise, Shaefer, Mark S

“…Pre-existing HIV drug resistance can jeopardize first-line antiretroviral therapy (ART) success. Changes in the prevalence of drug resistance-associated…”
Get more information

HLA-B57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B57:01-negative subjects by Small, Catherine Butkus, Margolis, David A, Shaefer, Mark S, Ross, Lisa L

“…The presence of the HLA-B*57:01 allele in HIV-infected subjects is associated with a higher risk of abacavir-associated hypersensitivity reaction (ABC HSR)…”
Get full text

HLA-B57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA ® observational database: a cohort study by Mounzer, Karam, Hsu, Ricky, Fusco, Jennifer S, Brunet, Laurence, Henegar, Cassidy E, Vannappagari, Vani, Stainsby, Chris M, Shaefer, Mark S, Ragone, Leigh, Fusco, Gregory P

“…HLA-B*57:01 screening was added to clinical care guidelines in 2008 to reduce the risk of hypersensitivity reaction from abacavir. The uptake of HLA-B*57:01…”
Get full text

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min by Ross, Lisa L, Walker, A Sarah, Lou, Yu, Tenorio, Allan R, Gibb, Diana M, Double, Julia, Gilks, Charles, McCoig, Cynthia C, Munderi, Paula, Musoro, Godfrey, Kityo, Cissy M, Grosskurth, Heiner, Hakim, James, Mugyenyi, Peter N, Cutrell, Amy, Perger, Teodora, Shaefer, Mark S

“…A retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults…”
Get full text

Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open‐Label, Randomized Study by Adkison, Kimberly, Wolstenholme, Allen, Lou, Yu, Zhang, Zhiping, Eld, Amy, Perger, Teodora, Vangerow, Harald, Hayward, Katy, Shaefer, Mark, McCoig, Cynthia

“…In children aged ≤4 years, the relative bioavailability of lamivudine oral solution was 37% lower than that of a tablet formulation. An open‐label, four‐way…”
Get full text

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) by Chounta, Vasiliki, Overton, Edgar T., Mills, Anthony, Swindells, Susan, Benn, Paul D., Vanveggel, Simon, van Solingen-Ristea, Rodica, Wang, Yuanyuan, Hudson, Krischan J., Shaefer, Mark S., Margolis, David A., Smith, Kimberly Y., Spreen, William R.

“…Background Advances in HIV-1 therapeutics have led to the development of a range of daily oral treatment regimens, which share similar high efficacy rates…”
Get full text

To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment by Mounzer, Karam, Brunet, Laurence, Wyatt, Christina M., Fusco, Jennifer S., Vannappagari, Vani, Tenorio, Allan R., Shaefer, Mark S., Ragone, Leigh, Hsu, Ricky K., Fusco, Gregory P.

“…Objectives: To assess the risk of adverse diagnoses and laboratory abnormalities associated with a 300 or 150 mg daily dose of lamivudine (3TC) initiated by…”
Get full text

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment by SMITH, Kimberly Y, PATEL, Parul, WANNAMAKER, Paul, SHAEFER, Mark S, FINE, Derek, BELLOS, Nicholaos, SLOAN, Louis, LACKEY, Philip, KUMAR, Princy N, SUTHERLAND-PHILLIPS, Denise H, VAVRO, Cindy, LINDA YAU

“…Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1…”
Get full text

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial by Wohl, David A, Bhatti, Laveeza, Small, Catherine B, Edelstein, Howard, Zhao, Henry H, Margolis, David A, DeJesus, Edwin, Weinberg, Winkler G, Ross, Lisa L, Shaefer, Mark S

“…Simplification of antiretroviral therapy in patients with suppressed viremia may minimize long-term adverse effects. The study's primary objective was to…”
Get full text

To dose-adjust or not to dose-adjust: 3TC dose in kidney impairment by Mounzer, Karam, Brunet, Laurence, Wyatt, Christina M., Fusco, Jennifer S., Vannappagari, Vani, Tenorio, Allan R., Shaefer, Mark S., Ragone, Leigh, Hsu, Ricky K., Fusco, Gregory P.

“…To assess the risk of adverse diagnoses and laboratory abnormalities associated with a 300 mg or 150 mg daily dose of 3TC initiated by people living with HIV…”
Get full text

Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort by Mounzer, Karam C, Fusco, Jennifer S, Hsu, Ricky K, Brunet, Laurence, Vannappagari, Vani, Frost, Kevin R, Shaefer, Mark S, Rinehart, Alex, Rawlings, Keith, Fusco, Gregory P

“…Preventing HIV transmission is a crucial step in ending the HIV epidemic. Safe and effective pre-exposure prophylaxis (PrEP) has been available in the United…”
Get more information

New genetic predictors for abacavir tolerance in HLA-B57:01 positive individuals by Pavlos, Rebecca, Deshpande, Pooja, Chopra, Abha, Leary, Shay, Strautins, Kaija, Nolan, David, Thorborn, Daren, Shaefer, Mark, Rauch, Andri, Dunn, David, Montaner, Julio, Rachlis, Anita, Almeida, Coral-Ann, Choo, Linda, James, Ian, Redwood, Alec J., Li, Yueran, Gaudieri, Silvana, Mallal, Simon A., Phillips, Elizabeth J.

“…Abacavir hypersensitivity syndrome (ABC HSS) is strongly associated with carriage of human leukocyte antigen (HLA)-B*57:01, which has a 100% negative…”
Get full text

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B5701 Screening as a Risk‐Mitigation Measure by Stainsby, Chris M., Perger, Teodora M., Vannappagari, Vani, Mounzer, Karam C., Hsu, Ricky K., Henegar, Cassidy E., Oyee, James, Urbaityte, Rimgaile, Lane, Charlotte E., Carter, Lindsay M., Pakes, Gary E., Shaefer, Mark S.

“…Introduction Human leukocyte antigen (HLA)‐B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening…”
Get full text

Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV-Infected Antiretroviral-Naive Subjects by Gallant, Joel E., Rodriguez, Allan E., Weinberg, Winkler G., Young, Benjamin, Berger, Daniel S., Lim, Michael L., Liao, Qiming, Ross, Lisa, Johnson, Judy, Shaefer, Mark S.

“…BackgroundAntiretroviral combinations that reduce the number of pills and dosing frequency have the potential to simplify therapy. We compared 2 regimens dosed…”
Get full text

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir by Robertson, Kevin, Maruff, Paul, Ross, Lisa L., Wohl, David, Small, Catherine B, Edelstein, Howard, Shaefer, Mark S.

“…Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral…”
Get full text

HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing by Ross, Lisa L, Horton, Joseph, Hasan, Samiul, Brown, James R, Murphy, Daniel, DeJesus, Edwin, Potter, Martin, LaMarca, Anthony, Melendez-Rivera, Ivan, Ward, Douglas, Uy, Jonathon, Shaefer, Mark S

“…Factors that contribute to the transmission of human immunodeficiency virus type 1 (HIV-1), especially drug-resistant HIV-1 variants remain a significant…”
Get full text

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients by SQUIRES, Kathleen E, YOUNG, Benjamin, DEJESUS, Edwin, BELLOS, Nicholaos, MURPHY, Daniel, ZHAO, Henry H, PATEL, Lisa G, ROSS, Lisa L, WANNAMAKER, Paul G, SHAEFER, Mark S

“…Treatment simplification strategies involving induction with a ritonavir (RTV)-boosted (/r) protease inhibitor regimen followed by simplification (without RTV)…”
Get full text

Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine by Bartlett, John A, Johnson, Judy, Herrera, Gisela, Sosa, Nestor, Rodriguez, Alan, Liao, Qiming, Griffith, Sandy, Irlbeck, David, Shaefer, Mark S

“…OBJECTIVE:To compare alternative class-sparing antiretroviral regimens in treatment-naive subjects. DESIGN:Open-label, multicenter, randomized trial of up to 3…”
Get full text

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES by Young, Benjamin, Squires, Kathleen E, Ross, Lisa L, Santiago, Lizette, Sloan, Louis M, Zhao, Henry H, Wine, Brian C, Pakes, Gary E, Margolis, David A, Shaefer, Mark S

“…Propensity for developing coronary heart disease (CHD) is linked with Framingham-defined cardiovascular risk factors and elevated inflammatory biomarkers…”
Get more information

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks by Squires, Kathleen E, Young, Benjamin, Santiago, Lizette, Dretler, Robin H, Walmsley, Sharon L, Zhao, Henry H, Pakes, Gary E, Ross, Lisa L, Shaefer, Mark S

“…The 144-week results of the open-label, multicenter Atazanavir/Ritonavir Induction with Epzicom Study (ARIES) were stratified by gender to compare treatment…”
Get full text